Brokerages expect that Seres Therapeutics Inc (NASDAQ:MCRB) will announce earnings per share (EPS) of ($0.42) for the current quarter, according to Zacks. Three analysts have made estimates for Seres Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.40). Seres Therapeutics posted earnings of ($0.68) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.2%. The firm is scheduled to issue its next earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Seres Therapeutics will report full year earnings of ($1.90) per share for the current financial year, with EPS estimates ranging from ($2.31) to ($1.26). For the next year, analysts expect that the company will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.52) to ($1.21). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.12). The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $8.61 million. Seres Therapeutics had a negative return on equity of 1,583.95% and a negative net margin of 301.60%.
NASDAQ:MCRB opened at $4.60 on Monday. The stock has a market capitalization of $196.43 million, a P/E ratio of -1.89 and a beta of 1.80. Seres Therapeutics has a one year low of $4.42 and a one year high of $9.75.
A number of hedge funds have recently modified their holdings of MCRB. BlackRock Inc. boosted its stake in Seres Therapeutics by 1.8% in the third quarter. BlackRock Inc. now owns 2,281,563 shares of the biotechnology company’s stock valued at $17,318,000 after acquiring an additional 40,719 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Seres Therapeutics by 6.4% during the third quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock valued at $3,199,000 after buying an additional 25,287 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Seres Therapeutics by 3.4% during the third quarter. Renaissance Technologies LLC now owns 756,608 shares of the biotechnology company’s stock valued at $5,743,000 after buying an additional 24,708 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Seres Therapeutics by 48.8% during the fourth quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 8,895 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Seres Therapeutics by 7.6% during the fourth quarter. Bank of New York Mellon Corp now owns 85,364 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 6,023 shares during the last quarter. Institutional investors own 79.26% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Featured Story: How do taxes affect a CDs total return?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.